Ocaliva (5mg, 10mg) is a structural modification of chenodeoxycholic acid 6-ethyl chenodeoxycholic acid, which is developed by Intercept Pharmacy for the development of a farnesyl X receptor agonist, by activating farnesol X (CYP7A1) gene expression, and thus inhibit bile acid synthesis, can be used for the treatment of primary biliary cholangitis (PBC) and nonalcoholic fatty liver disease (P <0.05) NASH). May 27, 2016 FDA officially approved the treatment of primary bile cholangitis orphanate indications, can be combined with ursodeoxycholic acid treatment of adult PBC or ursodeoxycholic acid can not tolerate a single treatment.  The drug is the first treatment of PBC drugs approved in nearly 20 years.
The results of a Phase III POISE clinical trial for PBC have shown that oubbic acid can significantly reduce the serum alkaline phosphatase content, which is a biomarker of progression of PBC progress, and alkalinity in the placebo group. The average phosphatase decreased by 5% compared with the baseline, while the 10 mg amberbic acid group and the 5-10 mg oxibenic acid group decreased by 39% and 33%, respectively. After 12 months of treatment, the proportion of patients in the placebo group reached the primary end point was 10%, compared with 47% and 46% for 10 mg of the oberanic acid group and 5-10 mg of the oubelic acid group, respectively. According to EvaluatePharma, Orbenic Acid will reach $ 3 billion in sales in 2020. Intercept Pharmaceuticals revealed that the average treatment cost of its oberic acid was $ 6.935 million, which was mainly due to the risk-benefit ratio and rare disease.